NeuroHealth
Translating neuroscience discoveries into treatments
Understanding the brain in health and disease will improve treatments for ourselves and our loved ones. Our clinical scientists not only treat patients, but are also working with basic scientists to pioneer novel treatments for psychiatric and neurological disease. Ongoing research aims to reverse brain aging, ease the devastating consequences of stroke, and develop non-invasive treatments to modulate brain activity associated with epilepsy and other neurological diseases. Breakthrough improvements in brain and mental health benefit not just individuals, but society as a whole.
Funded Research - Big Idea
Developing brain organoids – three dimensional brain tissues grown in the lab – to study human brain development, evolution and neuropsychiatric disorders.
Funded Research - Postdoctoral Fellowship
Spinal cord injury (SCI) is a debilitating condition that affects young adults between the ages of 16 and 30, which leads to lifelong medical and financial burdens. SCI still results in a decreased quality-of-life and lower life expectancy for patients. This is due in part to the lack of a regenerative-based therapeutic approach to treating SCI in the clinic.
News - Mar 8 2021
Everyday Health
News - Mar 25 2021
Exploring Drug Discovery and Development
News - Apr 2 2021
Stanford Medicine
Funded Research - Neuroscience:Translate
This team is developing a device that will enable accurate diagnosis of Parkinson’s disease via telemedicine. They initially introduced the technology of Quantitative DigitoGraphy (QDG) using a repetitive alternating finger tapping (RAFT) task on a musical instrument digital interface (MIDI) keyboard and will use Neuroscience: Translate funding for the next stage of device development.
Funded Research - Neuroscience:Translate
There are currently no available drugs for neurodegenerative diseases, including Alzheimer’s disease. Using the power of a new vertebrate aging model, the African killifish, this team is investigating age-dependent protein aggregation at a systems level and identifying aggregating proteins in the aging brain. There is huge potential to optimize the killifish platform for phenotypic screening of drug libraries, notably those targeted at protein aggregation, which is central to neurodegenerative diseases.
